Methylprednisolone improves IVIG treatment of children with Covid19/MIS-C


In a recent article in JAMA, a French consortium coordinated by François Angoulvant (Team “Data- and knowledge-driven approaches for precision medicine” at CRC) shows that combining corticosteroids with current intravenous immunoglobulin (IVIG) therapy improves the outcome of multisystemic inflammatory system in children (MIS-C) associated with Sars-Cov-2 infection.

The multicenter study included a total of 111 children, 34 of whom received methylprednisolone plus IVIG, and 72 received IVIG alone. Of the patients who received a combination of IVIG and methylprednisolone, 91% responded favorably to treatment at 48 hours compared with only 49% of those who received IVIG alone.

These data should lead to a change in the management of children with this disease, which affected more than 350 patients in France between April 2019 and January 2021.